From October 2010 to February 2011, biotech Clinical Data’s stock doubled, mostly thanks to FDA approval of its novel antidepressant. But also pushing the stock up — and making it likely to perhaps double again — is speculation that a Big Pharma will buy Clinical Data.
Continue reading Inside Wall Street: Two Good Reasons for Clinical Data Shares to Soar Again
Inside Wall Street: Two Good Reasons for Clinical Data Shares to Soar Again originally appeared on DailyFinance on Mon, 14 Feb 2011 08:00:00.
Filed Under: Company News, Columns, Investing, Health Care, Pfizer, Stock Picks, Merck, GlaxoSmithKline, Eli Lilly